Gapping down
News:
- CALA -56% (announced the combination of telaglenastat and cabozantinib did not meet the primary endpoint of improving progression free survival (PFS) in the study population)
- HLF -6.3% (reports $600 mln repurchase of shares from Icahn Enterprises; Icahn representatives on Board of Directors step down)
- CHA -4.9% (NYSE to delist)
- CHL -3.6% (NYSE to delist)
- BCOR -2.5% (rebrands as Avantax Planning Partners)
- CHU -1.9% (NYSE to delist)
- MNR -1.8% (issues statement highlighting its track record and says it's reviewing Blackwells' previously announced acquisition proposal)
- PLX -1.7% (Protalix BioTherapeutics and Chiesi Global rare diseases announce final results of BRIDGE Phase III)
- VXX -0.8% (trading lower with US futures indicating gains of 0.5% in pre-mkt)
Analyst comments:
- AI -2.1% (initiated with an Underweight at Morgan Stanley)
- BA -1% (downgraded to Underperform from Mkt Perform at Bernstein)
- MIME -0.6% (downgraded to Market Perform from Outperform at BMO Capital Markets)